Atara Biotherapeutics, Inc. (ATRA) trades at a trailing P/E of 1.8, forward P/E of 2.3. Trailing earnings yield is 54.18%, forward earnings yield 42.74%. PEG 0.25 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 67/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -0.5 | -0.02 | 1.61 | 0.00 | - |
| 2017 | -0.5 | -0.01 | 3.04 | 0.00 | - |
| 2018 | -0.7 | -0.02 | 4.49 | 0.00 | - |
| 2019 | -2.9 | -0.38 | 2.91 | 0.00 | - |
| 2020 | -4.7 | 0.18 | 3.14 | 0.00 | - |
| 2021 | -4.3 | 0.35 | 5.28 | 72.58 | - |
| 2022 | -1.5 | 0.04 | 2.64 | 5.26 | - |
| 2023 | -0.2 | -0.01 | -0.55 | 6.34 | - |
| 2024 | -1.2 | 0.01 | -1.02 | 0.77 | - |
| 2025 | 6.9 | -0.06 | -5.89 | 1.88 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-68.78 | $0.00 | $-790.49M | - |
| 2017 | $-100.03 | $0.00 | $-1.19B | - |
| 2018 | $-131.64 | $0.00 | $-2.31B | - |
| 2019 | $-141.78 | $0.00 | $-2.91B | - |
| 2020 | $-103.63 | $0.00 | $-3.07B | - |
| 2021 | $-90.78 | $20.34M | $-3.4B | -16722.8% |
| 2022 | $-55.96 | $63.57M | $-2.28B | -3591.2% |
| 2023 | $-65.18 | $8.57M | $-276.13M | -3220.9% |
| 2024 | $-11.41 | $128.94M | $-85.4M | -66.2% |
| 2025 | $2.57 | $120.77M | $32.69M | 27.1% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.69 | $-0.69 – $-0.69 | $14.37M | $14.37M – $14.37M | 2 |
| 2027 | $-0.78 | $-0.78 – $-0.78 | $35.15M | $35.15M – $35.15M | 2 |
| 2028 | $-0.30 | $-2.35 – $1.86 | $46.9M | $46.9M – $46.9M | 4 |
| 2029 | $2.10 | $2.10 – $2.10 | $110M | $110M – $110M | 2 |
| 2030 | $2.10 | $2.10 – $2.10 | $123M | $123M – $123M | 2 |
